Laurus Labs gets USFDA approval for HIV drug

TLD is first-line regimen for patients

Published - February 03, 2019 10:53 pm IST - HYDERABAD

Pharma firm Laurus Labs has received tentative approval from the United States Food and Drug Administration for Tenofovir/Lamivudine/Dolutegravir (TLD) 300/300/50mg fixed dose combination drug.

The product is the preferred first-line regimen for the treatment of people living with HIV.

It will be available in the generic form in low and middle income countries, the company said on Sunday.

The U.S. health regulator had given the tentative approval under the Presidential Emergency Plan for AIDS Relief.

The U.S. Department of Health and Human Services Panel as well as WHO recommend TLD as one of the preferred first line regimen for such people.

Laurus Labs said it expected to commercialise “this important medicine in the access markets.” The product will be manufactured at the company’s Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam.

Company founder and CEO Satyanarayana Chava described it as a significant approval for Laurus Labs, which has forayed into finished dosage forms recently.

“This product would demonstrate the company’s capability to develop fixed dose combinations of ARVs,” he said.

Meanwhile, the company has received an Establishment Inspection Report (EIR) from USFDA for its Unit 6 on February 2.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.